Latest Blogs, Articles, and More
An analysis of patients with advanced hepatocellular carcinoma and elevated AFP who received second-line Cyramza showed improved survival, according to data from the phase 3 REACH study.
There is a lot of pressure on cancer patients to stay cheerful and only focus on the positive during treatment and beyond. I think this is overrated and can stifle the process of coming to terms with this disease.
Recent results from the phase 2 TERRAIN trial showed Xtandi increased progression-free survival by nearly 10 months compared with Casodex in patients with metastatic castration-resistant prostate cancer.
The integrative treatment of cancer must include nutrition as an adjunct to surgery, radiation therapy and chemotherapy.
Immune checkpoint inhibitors targeted against PD-1 and its ligand PD-L1 have rapidly advanced as treatments for patients with melanoma and non-small cell lung cancer (NSCLC), following their initial debut in 2012. What's next?